Resource Type

Journal Article 583

Conference Videos 7

Year

2024 1

2023 29

2022 51

2021 61

2020 34

2019 53

2018 42

2017 45

2016 29

2015 29

2014 25

2013 31

2012 24

2011 22

2010 15

2009 30

2008 12

2007 19

2006 4

2005 3

open ︾

Keywords

fuel cell 13

immunotherapy 8

solar cell 6

hematopoietic stem cell transplantation 5

hepatocellular carcinoma 5

hydrogen energy 5

stem cell 5

COVID-19 4

breast cancer 4

cell proliferation 4

control 4

immunity 4

lung cancer 4

microbial fuel cell 4

solid oxide fuel cell 4

High pressure 3

cancer immunotherapy 3

chemotherapy 3

prognosis 3

open ︾

Search scope:

排序： Display mode:

Regulation of T cell immunity by cellular metabolism

Zhilin Hu, Qiang Zou, Bing Su

Frontiers of Medicine 2018, Volume 12, Issue 4,   Pages 463-472 doi: 10.1007/s11684-018-0668-2

Abstract:

T cells are an important adaptive immune response arm that mediates cell-mediated immunity.T cell metabolism plays a central role in T cell activation, proliferation, differentiation, and effectorSpecific metabolic programs are tightly controlled to mediate T cell immune responses, and alterationsin T cell metabolism may result in many immunological disorders.in T cell metabolic programming during T cell homeostasis, differentiation, and function.

Keywords： T cell immunity     metabolic pathways     nutrient uptake     metabolic checkpoints    

HTML PDF Collect

Deubiquitinases as pivotal regulators of T cell functions

Xiao-Dong Yang, Shao-Cong Sun

Frontiers of Medicine 2018, Volume 12, Issue 4,   Pages 451-462 doi: 10.1007/s11684-018-0651-y

Abstract:

T cells efficiently respond to foreign antigens to mediate immune responses against infections butDefect in T cell activation is associated with severe immune deficiencies, whereas aberrant T cell activationAn emerging mechanism that regulates T cell activation and tolerance is ubiquitination, a reversibleIt is now well recognized that DUBs are crucial regulators of T cell responses and serve as potentialThis review will discuss the recent progresses regarding the functions of DUBs in T cells.

Keywords： deubiquitinase     ubiquitination     T cell activation     T cell differentiation     T cell tolerance    

HTML PDF Collect

CAR T-cell immunotherapy: a powerful weapon for fighting hematological B-cell malignancies

Frontiers of Medicine 2021, Volume 15, Issue 6,   Pages 783-804 doi: 10.1007/s11684-021-0904-z

Abstract: Chimeric antigen receptor T-cell (CAR T) immunotherapy opens a new path for targeted therapy of hematologicalIn this review, through a representative case study, we summarize the current experience of CAR T-cell, the causative mechanisms of therapy resistance, and new strategies to improve the efficacy of CAR T-cell

Keywords： CAR T cells     hematological malignancies     review    

HTML PDF Collect

High-affinity T cell receptors redirect cytokine-activated T cells (CAT) to kill cancer cells

Synat Kang, Yanyan Li, Yifeng Bao, Yi Li

Frontiers of Medicine 2019, Volume 13, Issue 1,   Pages 69-82 doi: 10.1007/s11684-018-0677-1

Abstract:

Cytokine-activated T cells (CATs) can be easily expanded and are widely applied to cancer immunotherapyThe low-efficacy problem can be resolved using T cell antigen receptor-engineered CAT (TCR-CAT).TCR-CATs delivered significantly better activation and cytotoxicity than the equivalent TCR-engineered Tinterferon-g and granzyme B production and in vitro cancer cellTCR-CAT may be a very good alternative to the expensive TCR-T, which is considered an effective personalized

Keywords： cytokine-activated T cells     high-affinity T cell receptor     cancer immunotherapy     TCR-CAT    

HTML PDF Collect

A giant step forward: chimeric antigen receptor T-cell therapy for lymphoma

Houli Zhao, Yiyun Wang, Elaine Tan Su Yin, Kui Zhao, Yongxian Hu, He Huang

Frontiers of Medicine 2020, Volume 14, Issue 6,   Pages 711-725 doi: 10.1007/s11684-020-0808-3

Abstract: Chimeric antigen receptor T (CAR-T) cells were introduced as a treatment for these patients.achieved complete remission after receiving the CD19 CAR-T cell therapy.cell therapy.Therefore, optimizing the structure of CAR, creating new drugs, and combining CAR-T cell therapy withthe toxicity in patients with lymphoma after the CAR-T cell therapy.

Keywords： chimeric antigen receptor T (CAR-T) cell     lymphoma     cytokine release syndrome (CRS)     immune effector cell-associated    

HTML PDF Collect

Chimeric antigen receptor T cell therapies for acute myeloid leukemia

Bin Gu, Jianhong Chu, Depei Wu

Frontiers of Medicine 2020, Volume 14, Issue 6,   Pages 701-710 doi: 10.1007/s11684-020-0763-z

Abstract: Abstract Chimeric antigen receptor T cell (CAR T) therapies have achieved unprecedented efficacy in B-cellAllogeneic hematopoietic stem cell transplantation could be an effective therapy because of the graft-versus-leukemiaAlthough the identification of an ideal target antigen for AML is challenging, CAR T therapy remainsIn this review, we focus on the most recent and promising advances in CAR T therapies for AML.

Keywords： acute myeloid leukemia     CAR T     immunotherapy    

HTML PDF Collect

Phase I study of CBM.CD19 chimeric antigen receptor T cell in the treatment of refractory diffuse largeB-cell lymphoma in Chinese patients

Frontiers of Medicine 2022, Volume 16, Issue 2,   Pages 285-294 doi: 10.1007/s11684-021-0843-8

Abstract: Anti-CD19 chimeric antigen receptor (CAR) T cell therapy has shown impressive efficacy in treating B-cellA single-center phase I dose-escalation study was conducted to evaluate the safety and efficacy of Tbearing 4-1BB costimulatory molecule, for the treatment of patients with refractory diffuse large B-cellTen heavily treated patients with refractory DLBCL were given CBM.CD19 CAR-T cell (C-CAR011) treatment

Keywords： CAR-T cell therapy     refractory diffuse large B-cell lymphoma     cytokine release syndrome     dose-limiting    

HTML PDF Collect

Chidamide inhibits the NOTCH1-MYC signaling axis in T-cell acute lymphoblastic leukemia

Frontiers of Medicine 2022, Volume 16, Issue 3,   Pages 442-458 doi: 10.1007/s11684-021-0877-y

Abstract: T-cell acute lymphoblastic leukemia (T-ALL) is one of the most dangerous hematological malignancies,More than 60% of T-ALL patients carry NOTCH1 gene mutations, leading to abnormal expression ofWe found that chidamide, an HDAC inhibitor, exerts an antitumor effect on T-ALL cell lines and primaryOur results highlight the effectiveness and safety of chidamide in the treatment of T-ALL patients, including

Keywords： T-cell acute lymphoblastic leukemia     HDAC inhibitor     chidamide     NOTCH1     MYC     ubiquitination    

HTML PDF Collect

Clinical characteristics and prognostic factors of patients with mature T-cell lymphoid malignancies:

Wen Xue,Yan Sheng,Xiangqin Weng,Yongmei Zhu,Yan Zhao,Pengpeng Xu,Xiaochun Fei,Xiaoyan Chen,Li Wang,Weili Zhao

Frontiers of Medicine 2015, Volume 9, Issue 4,   Pages 468-477 doi: 10.1007/s11684-015-0419-6

Abstract:

Mature T-cell lymphoid malignancies comprise a group of heterogeneous diseases that vary in clinicopathologicalBone marrow (BM) infiltration is more commonly present in mature T-cell lymphoid malignancies comparedthis study, clinical characteristics and prognostic factors were analyzed in 225 patients with mature T-cellThese included 29 cases of T-cell lymphoproliferative disorders (T-LPD, all with BM infiltration) and196 cases of T-/natural-killer-cell lymphoma (T/NKCL, 56 with BM infiltration and 140 without BM infiltration

Keywords： mature T-cell lymphoid malignancies     clonal T-cell population     bone marrow infiltration     prognostic factors    

HTML PDF Collect

Early T-cell precursor leukemia: a subtype of high risk childhood acute lymphoblastic leukemia

Meilin Ma, Xiang Wang, Jingyan Tang, Huiliang Xue, Jing Chen, Ci Pan, Hua Jiang, Shuhong Shen

Frontiers of Medicine 2012, Volume 6, Issue 4,   Pages 416-420 doi: 10.1007/s11684-012-0224-4

Abstract:

Acute lymphoblastic leukemia includes T-cell acute lymphoblastic leukemia (T-ALL) and B-cell acutephenotype that resembles early T-cell precursor, which confers a much poorer prognosis than any otherform of T-ALL.This novel subtype of T-ALL was called early T-cell precursor acute lymphoblastic leukemia (ETP-ALL).Our findings demonstrate that early T-cell precursor leukemia is a very high-risk subtype of acute lymphoblastic

Keywords： acute lymphoblastic leukemia     early T precursor     prognosis    

HTML PDF Collect

Chimeric antigen receptor T-cell therapy: a promising treatment modality for relapsed/refractory mantlecell lymphoma

Ping Li, Ningxin Dong, Yu Zeng, Jie Liu, Xiaochen Tang, Junbang Wang, Wenjun Zhang, Shiguang Ye, Lili Zhou, Alex Hongsheng Chang, Aibin Liang

Frontiers of Medicine 2020, Volume 14, Issue 6,   Pages 811-815 doi: 10.1007/s11684-020-0740-6

Abstract: Chimeric antigen receptor (CAR) T-cell therapy has emerged as a novel treatment modality for r/r non-HodgkinHowever, long-term safety and tolerability associated with CAR T-cell therapy are not defined well, especiallypatient with r/r MCL with 48-month duration of follow-up who achieved long-term remission after CAR T-cellCAR T-cell-related toxicities were also mild and tolerated well even in this elderly patient.This report suggested that CAR T-cell therapy is a promising treatment modality for patients with MCL

Keywords： anti-CD19 chimeric antigen receptor T cells     mantle cell lymphoma     relapsed or refractory     long-term follow-up    

HTML PDF Collect

Immunosuppressive tumor microenvironment contributes to tumor progression in diffuse large B-cell lymphomaupon anti-CD19 chimeric antigen receptor T therapy

Frontiers of Medicine 2023, Volume 17, Issue 4,   Pages 699-713 doi: 10.1007/s11684-022-0972-8

Abstract: Anti-CD19 chimeric antigen receptor (CAR)-T cell therapy has achieved 40%–50However, the underlying mechanism of alterations in the tumor microenvironments resulting in CAR-T cellcells, leading to CAR-T cell therapy failure and disease progression in DLBCL.Immunosuppressive tumor microenvironments persisted before CAR-T cell therapy, during both cell expansioncell therapy.

Keywords： anti-CD19 chimeric antigen receptor T     immunotherapy     diffuse large B cell lymphoma     tumor microenvironment    

HTML PDF Collect

Effect on proliferation and apoptosis of T24 cell lines via silencing DNMT1 with RNA interference

ZHANG Shilong, ZENG Fuqing, PENG Shibo, WANG Liang

Frontiers of Medicine 2008, Volume 2, Issue 4,   Pages 374-379 doi: 10.1007/s11684-008-0072-4

Abstract: In this study, the eukaryotic vector pshRNA-DNMT1 was constructed and transfected into T24 cells.48th and 72nd hour after transfection of pshRNA-DNMT1, the inhibitory rates of DNMT1 mRNA levels in T24between pshRNA-DNMT1 and the control blank at each time points ( < 0.01); 24, 48 and 72 hours after T24and protein effectively, and to some extent, it also can inhibit the proliferation of bladder cancer cell
HTML PDF Collect

Durability of neutralizing antibodies and T-cell response post SARS-CoV-2 infection

Yun Tan, Feng Liu, Xiaoguang Xu, Yun Ling, Weijin Huang, Mingquan Guo, Ziyu Fu, Dongguo Liang, Miao Xu, Hongzhou Lu, Saijuan Chen

Frontiers of Medicine 2020, Volume 14, Issue 6,   Pages 746-751 doi: 10.1007/s11684-020-0822-5

Abstract: How long the adaptive immunity triggered by SARS-CoV-2 can last is of critical clinical relevance inshowed significant neutralizing activities in a pseudovirus assay, with no difference in blocking the cell-entryFurthermore, in 10 blood samples from cases at 6−7 months post-infection used for memory T-cell testsTogether, these results indicate that durable anti-SARS-CoV-2 immunity is common in convalescent population

Keywords： SARS-CoV-2     neutralizing antibodies     T-cell response    

HTML PDF Collect

survival of patients with relapsed or refractory non-Hodgkin lymphoma after chimeric antigen receptor Tcell therapy

Lili Zhou, Ping Li, Shiguang Ye, Xiaochen Tang, Junbang Wang, Jie Liu, Aibin Liang

Frontiers of Medicine 2020, Volume 14, Issue 6,   Pages 786-791 doi: 10.1007/s11684-020-0751-3

Abstract: Factors associated with complete and durable remissions after anti-CD19 chimeric antigen receptor T (CAR-T) cell immunotherapy for relapsed or refractory non-Hodgkin lymphoma (r/r NHL) have not been wellsurvival (OS), and progression-free survival (PFS) in patients with r/r NHL treated with anti-CD19 CAR-Tcell therapy.Thus, anti-CD19 CAR-T cell therapy may improve the prognosis of patients with BM infiltration.

Keywords： anti-CD19 chimeric antigen receptor T cell     soft tissue     bone marrow     relapsed or refractory non-Hodgkin    

HTML PDF Collect

Title Author Date Type Operation

Regulation of T cell immunity by cellular metabolism

Zhilin Hu, Qiang Zou, Bing Su

Journal Article

Deubiquitinases as pivotal regulators of T cell functions

Xiao-Dong Yang, Shao-Cong Sun

Journal Article

CAR T-cell immunotherapy: a powerful weapon for fighting hematological B-cell malignancies

Journal Article

High-affinity T cell receptors redirect cytokine-activated T cells (CAT) to kill cancer cells

Synat Kang, Yanyan Li, Yifeng Bao, Yi Li

Journal Article

A giant step forward: chimeric antigen receptor T-cell therapy for lymphoma

Houli Zhao, Yiyun Wang, Elaine Tan Su Yin, Kui Zhao, Yongxian Hu, He Huang

Journal Article

Chimeric antigen receptor T cell therapies for acute myeloid leukemia

Bin Gu, Jianhong Chu, Depei Wu

Journal Article

Phase I study of CBM.CD19 chimeric antigen receptor T cell in the treatment of refractory diffuse largeB-cell lymphoma in Chinese patients

Journal Article

Chidamide inhibits the NOTCH1-MYC signaling axis in T-cell acute lymphoblastic leukemia

Journal Article

Clinical characteristics and prognostic factors of patients with mature T-cell lymphoid malignancies:

Wen Xue,Yan Sheng,Xiangqin Weng,Yongmei Zhu,Yan Zhao,Pengpeng Xu,Xiaochun Fei,Xiaoyan Chen,Li Wang,Weili Zhao

Journal Article

Early T-cell precursor leukemia: a subtype of high risk childhood acute lymphoblastic leukemia

Meilin Ma, Xiang Wang, Jingyan Tang, Huiliang Xue, Jing Chen, Ci Pan, Hua Jiang, Shuhong Shen

Journal Article

Chimeric antigen receptor T-cell therapy: a promising treatment modality for relapsed/refractory mantlecell lymphoma

Ping Li, Ningxin Dong, Yu Zeng, Jie Liu, Xiaochen Tang, Junbang Wang, Wenjun Zhang, Shiguang Ye, Lili Zhou, Alex Hongsheng Chang, Aibin Liang

Journal Article

Immunosuppressive tumor microenvironment contributes to tumor progression in diffuse large B-cell lymphomaupon anti-CD19 chimeric antigen receptor T therapy

Journal Article

Effect on proliferation and apoptosis of T24 cell lines via silencing DNMT1 with RNA interference

ZHANG Shilong, ZENG Fuqing, PENG Shibo, WANG Liang

Journal Article

Durability of neutralizing antibodies and T-cell response post SARS-CoV-2 infection

Yun Tan, Feng Liu, Xiaoguang Xu, Yun Ling, Weijin Huang, Mingquan Guo, Ziyu Fu, Dongguo Liang, Miao Xu, Hongzhou Lu, Saijuan Chen

Journal Article

survival of patients with relapsed or refractory non-Hodgkin lymphoma after chimeric antigen receptor Tcell therapy

Lili Zhou, Ping Li, Shiguang Ye, Xiaochen Tang, Junbang Wang, Jie Liu, Aibin Liang

Journal Article